Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ruxolitinib phosphate (INCB018424) 是一种 JAK1/2抑制剂,IC50分别为3.3 nM/2.8 nM,对 JAK1/2 的选择性是 JAK3 的 130 倍以上。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
5 mg | ¥ 297 | 现货 | ||
10 mg | ¥ 442 | 现货 | ||
25 mg | ¥ 727 | 现货 | ||
50 mg | ¥ 1,270 | 现货 | ||
100 mg | ¥ 2,360 | 现货 | ||
200 mg | ¥ 3,750 | 现货 | ||
500 mg | ¥ 5,430 | 现货 | ||
1 g | ¥ 7,620 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 379 | 现货 |
产品描述 | Ruxolitinib phosphate (INCB018424)(INCB018424 phosphate) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. |
靶点活性 | JAK2:2.8 nM, JAK1:3.3 nM |
体外活性 | Ruxolitinib (INCB018424) potently and selectively inhibits JAK2V617F-mediated signaling and proliferation. Ruxolitinib inhibits the growth of HEL cells with EC50 of 186 nM. Ruxolitinib markedly increases apoptosis in Ba/F3-EpoR-JAK2V617F cell system. It also inhibits hematopoietic progenitor cell proliferation in primary MPN patient samples[1]. |
体内活性 | Ruxolitinib (180 mg/kg, p.o.) reduces the tumor burden of mice inoculated with JAK2V617F-expressing cells while not causing anemia or lymphopenia[1]. |
细胞实验 | Ruxolitinib phosphate is dissolved in 0.2% DMSO. Cells are seeded at 2000/well of white bottom 96-well plates, treated with compounds from DMSO stocks (0.2% final DMSO concentration), and incubated for 48 hours at 37°C with 5% CO2. Viability is measured by cellular ATP determination using the Cell-Titer Glo luciferase reagent or viable cell counting. Values are transformed to percent inhibition relative to vehicle control, and IC50?curves are fitted according to nonlinear regression analysis of the data using PRISM GraphPad. |
别名 | INC424, INCB018424, INC 424 phosphate, Ruxolitinib (INCB-18424) phosphate, INCB018424 phosphate, 磷酸鲁索利替尼 |
化合物与蛋白结合的复合物 |
C-Src in complex with Ruxolitinib |
分子量 | 404.36 |
分子式 | C17H21N6O4P |
CAS No. | 1092939-17-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 70 mg/mL(173.1 mM)
H2O: 8 mg/mL(19.8 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO / H2O | 1 mM | 2.473 mL | 12.3652 mL | 24.7304 mL | 61.8261 mL |
5 mM | 0.4946 mL | 2.473 mL | 4.9461 mL | 12.3652 mL | |
10 mM | 0.2473 mL | 1.2365 mL | 2.473 mL | 6.1826 mL | |
DMSO | 20 mM | 0.1237 mL | 0.6183 mL | 1.2365 mL | 3.0913 mL |
50 mM | 0.0495 mL | 0.2473 mL | 0.4946 mL | 1.2365 mL | |
100 mM | 0.0247 mL | 0.1237 mL | 0.2473 mL | 0.6183 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Ruxolitinib phosphate 1092939-17-7 Angiogenesis Autophagy Chromatin/Epigenetic JAK/STAT signaling Stem Cells Mitophagy JAK Ruxolitinib inhibit INCB 018424 Phosphate INCB 018424 INCB-018424 INC424 INC424 Phosphate Mitochondrial Autophagy Ruxolitinib Phosphate INCB018424 INC 424 phosphate INC 424 INC-424 Phosphate Inhibitor INC 424 Phosphate INCB-018424 Phosphate INCB018424 Phosphate Ruxolitinib (INCB-18424) phosphate INCB018424 phosphate 磷酸鲁索利替尼 Ruxolitinib (INCB-18424) Phosphate INC-424 Janus kinase inhibitor